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Abstract
Background: Infants presenting with lysosomal acid lipase deficiency have marked failure to thrive, diarrhea,
massive hepatosplenomegaly, anemia, rapidly progressive liver disease, and death typically in the first 6 months of
life; the only available potential treatment has been hematopoietic stem cell transplantation, which is associated
with high morbidity and mortality in this population. The study objective was to evaluate safety and efficacy
(including survival) of enzyme replacement with sebelipase alfa in infants with lysosomal acid lipase deficiency. This
is an ongoing multicenter, open-label, phase 2/3 study conducted in nine countries. The study enrolled infants with
growth failure prior to 6 months of age with rapidly progressive lysosomal acid lipase deficiency; they received
once-weekly doses of sebelipase alfa initiated at 0.35 mg/kg with intrapatient dose escalation up to 5 mg/kg. The
main outcome of interest is survival to 12 months and survival beyond 24 months of age.
Results: Nine patients were enrolled; median age at baseline was 3.0 months (range 1.1–5.8 months). Sixty-seven
percent (exact 95% CI 30%–93%) of sebelipase alfa–treated infants survived to 12 months of age compared with
0% (exact 95% CI 0%–16%) for a historical control group (n = 21). Patients who survived to age 12 months exhibited
improvements in weight-for-age, reductions in markers of liver dysfunction and hepatosplenomegaly, and
improvements in anemia and gastrointestinal symptoms. Three deaths occurred early (first few months of life), two
patients died because of advanced disease, and a third patient died following complications of non-protocol-
specified abdominal paracentesis. A fourth death occurred at 15 months of age and was related to other clinical
conditions. The five surviving patients have survived to age ≥24 months with continued sebelipase alfa treatment;
all have displayed marked improvement in growth parameters and liver function. Serious adverse events considered
related to sebelipase alfa were reported in one of the nine infants (infusion reaction: tachycardia, pallor, chills, and
pyrexia). Most infusion-associated reactions were mild and non-serious.
Conclusion: Sebelipase alfa markedly improved survival with substantial clinically meaningful improvements in
growth and other key disease manifestations in infants with rapidly progressive lysosomal acid lipase deficiency
Trial registration: Clinicaltrials.gov NCT01371825. Registered 9 June 2011.
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Background
Lysosomal acid lipase (LAL) deficiency is an autosomal-
recessive disorder due to deficiency of LAL, the enzyme
that hydrolyzes cholesteryl esters and triglycerides (Online
Mendelian Inheritance in Man® database #278000) [1].
The enzyme deficiency is due to LIPA mutations and leads
to lysosomal lipid accumulation in many types of cells and
tissues [2, 3]. Like other lysosomal storage diseases, this
disease presents across an age continuum from infancy to
adulthood [4]. The most rapidly progressive presentation
of LAL deficiency occurs in infants (in infants, LAL
deficiency has historically been known as Wolman
disease [5, 6]), and usually leads to death before
6 months of age [2, 7]. Affected infants show evi-
dence of the disease within the first few months of
life, with diarrhea, marked failure to thrive, abdominal
distension, massive hepatosplenomegaly, anemia, and
rapidly progressive liver dysfunction. Affected children
and adults demonstrate a number of abnormalities
similar to those seen in infants, including hepatomeg-
aly, elevated serum transaminase levels, liver fibrosis,
and dyslipidemia with progression to cirrhosis, and
other complications related to end-stage liver disease
[2, 4, 8, 9]. Enzyme replacement with sebelipase alfa
in children and adults has recently been shown to
produce significant improvements in a broad range of
disease-related manifestations [10].
Although the disease presentation in infants is striking,
familiarity with the disease is low and there are a num-
ber of published cases where the correct diagnosis was
not made until after death [11]. In untreated infants the
disease progresses rapidly, with death occurring within a
few weeks after diagnosis (median age at death, 3.7 months)
[7]. Prior to the availability of sebelipase alfa, treatment
options centered upon supportive interventions, including
blood transfusions and nutritional supplementation.
Hematopoietic stem cell transplantation (HSCT) and liver
transplantation have been used in a small number of cases
but outcomes remain very poor, with few reported survi-
vors of HSCT [12–17]. In case reports involving a total of
12 patients with early-onset LAL deficiency who received
HSCT, nine patients died within 8 months post-transplant
and one died approximately 6 years after receiving HSCT;
most of these deaths resulted from either progression of
LAL deficiency or HSCT-related complications such as
infection, graft-versus-host disease, and/or graft failure.
Enzyme replacement therapy (ERT) has had a dra-
matic impact in a number of lysosomal storage disorders
including Gaucher disease, Fabry disease, Pompe disease,
and the mucopolysaccharidoses. Sebelipase alfa (Alexion
Pharmaceuticals, Inc., New Haven, Connecticut, USA) is
a recombinant human LAL developed as an ERT for
LAL deficiency [18]. Here we report survival to
12 months of age (the primary endpoint), survival to
24 months of age, safety, and disease-related outcomes
in infants with rapidly progressive LAL deficiency who
received sebelipase alfa.
Methods
Study design and patients
This is an ongoing, global, phase 2/3, open-label, repeat-
dose, intrapatient dose-escalation study of the efficacy
and safety of sebelipase alfa in infants (VITAL, Survival
of LAL-D Infants Treated With Sebelipase Alfa;
NCT01371825) [19]. Twelve centers in nine countries
are participating (Additional file 1, eStudy centers), with
initiation on April 11, 2011. Patients were enrolled over
a 2.5-year period and the data cut-off date for analysis of
survival to 12 months of age (primary endpoint) was
June 10, 2014. All surviving patients continue to receive
sebelipase alfa treatment in an ongoing extension study;
the cut-off date for analysis of survival to 24 months of
age was January 26, 2016. Patients received sebelipase
alfa, with treatment initiated at 0.35 mg/kg once weekly
and escalation up to 3 mg/kg based on clinical response
(Additional file 1, eDose adjustment based on clinical re-
sponse). A further dose escalation to 5 mg/kg once
weekly was allowed upon consultation between the
investigator and study sponsor, including instances
where there was insufficient clinical response in patients
with potentially neutralizing anti-drug antibodies (ADAs;
Additional file 1, eMeasurements). Reduced dosing fre-
quency to once every other week was allowed, based on
clinical response and investigator discretion in consult-
ation with the sponsor. The rapid disease progression and
high mortality rate in patients with LAL deficiency
precluded the use of a placebo control group in this
study; a population of untreated LAL-deficient pa-
tients with growth failure from a natural history study
served as a historical control group (data on file,
Alexion Pharmaceuticals, Inc.) [7].
Eligible patients were under 8 months of age as of the
date of the anticipated first infusion, had a diagnosis of
LAL deficiency confirmed (with LAL enzyme activity
testing and/or LIPA mutation analysis), and demon-
strated growth failure or other evidence of rapidly pro-
gressive disease with onset before 6 months of age
(Additional file 1, eEvidence of rapidly progressive dis-
ease as inclusion criterion). Growth failure criteria were
weight decreasing across two or more of the 11 major
centiles (99th, 97th, 95th, 90th, 75th, 50th, 25th, 10th, 5th, 3rd,
1st) on a standard World Health Organization (WHO)
weight-for-age (WFA) chart, or body weight below the 10th
centile on a standard WHOWFA chart and no weight gain
during the 2 weeks before screening, or loss of greater than
5% of birth weight after 2 weeks of age. Key exclusion
criteria included myeloablative preparation or other trans-
plant conditioning and previous HSCT or liver transplant.
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The primary objective was to evaluate the effect of sebeli-
pase alfa therapy on survival at 12 months of age in LAL-
deficient infants with growth failure. Secondary objectives
included evaluation of safety, survival at 6-month intervals
after 12 months of age, changes in centiles for WFA and
length-for-age (LFA) [20], growth status indicators of under-
weight, wasting, and stunting [21], markers of liver injury
(alanine aminotransferase [ALT], aspartate aminotransferase
[AST]), liver function (total bilirubin, γ-glutamyltransferase
[GGT], and alkaline phosphatase), transfusion-free
hemoglobin normalization (TFHN; Additional file 1
[eDefinition of transfusion-free hemoglobin normalization]
for description), and changes in liver and spleen size and
volume, based on physical examination and ultrasound at
scheduled time points (physical examination: weeks 3, 9,
15, 20, and 24, and every 3 months thereafter; abdominal
ultrasound: weeks 0, 12, 24, and annually thereafter).
Adverse events data are being collected and analyzed on an
ongoing basis. Exploratory objectives included the effects of
sebelipase alfa on serum lipid levels (low-density lipoprotein
cholesterol, triglycerides, high-density lipoprotein choles-
terol, and total cholesterol). The Denver II Developmental
Screening Test [22] for evaluating fine motor–adaptive,
gross motor, language, and personal-social skills (per-
formance-based and parent-reported) was also in-
cluded. Results for each of the four assessment
categories of the test were interpreted by the evaluator
as “normal”, “suspect”, or “untestable”.
Safety was assessed by ascertainment of adverse events,
discontinuations, deaths, infusion-associated reactions
(IARs; Additional file 1, eDefinition of infusion-associated
reaction), ADAs, clinical laboratory tests, vital signs, phys-
ical examinations, and electrocardiograms.
Statistical analysis
The primary efficacy set was defined as patients in the
full analysis set who were 8 months of age or younger
on the date of their first infusion (n = 9). Survival was
compared to survival in a historical cohort of untreated
infants with confirmed diagnosis of LAL deficiency, who
had similar clinical characteristics (data on file, Alexion
Pharmaceuticals, Inc.) [7]. All hematological, liver bio-
chemical, and lipid analyses were performed by local
laboratories, and assessed using age- and gender-specific
normal values at the time of the test. Details of planned
statistical methods including sample size are described
in Additional file 1 (eStatistical methods and determination
of sample size).
Results
Patient characteristics and treatment
Nine patients were enrolled and received weekly infusions
of sebelipase alfa (Fig. 1). The median age of patients at
the time of initiation of treatment was 3.0 months (range
1.1–5.8 months); eight of the nine patients met the pre-
specified growth failure criteria. In seven of the nine
patients, sebelipase alfa doses were escalated to once-
weekly doses of 1 mg/kg, 3 mg/kg, or 5 mg/kg. One
patient with neutralizing antibodies and less-than-
expected improvements in growth compared with other
infants received a dose increase to 5 mg/kg. A second
patient had doses escalated to 5 mg/kg weekly due to
persistence of elevated transaminase levels, hypoalbumin-
emia, poor weight gain, and poor general well-being. At
the primary analysis data cut-off date, patients had
received a total of 462 infusions (including 141 infusions
at 1.0 mg/kg, 295 infusions at 3.0 mg/kg, and 8 infusions
at 5.0 mg/kg). Median duration of exposure was
60.3 weeks (range 0.1–164.7 weeks). At the follow-up cut-
off date (January 26, 2016) for the five patients surviving
to age 24 months, a total of 838 sebelipase alfa infusions
had been administered. All five ongoing patients had
required a dose escalation to 3.0 mg/kg and two patients
were receiving 5.0 mg/kg. The protocol contains clear
criteria for dose escalation (Additional file 1, eDose
adjustment based on clinical response), first to 3 mg/kg
and then to 5 mg/kg. As well as these criteria, other
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Fig. 1 Patient flow and disposition. Two patients died during
screening; three patients died after enrollment, all of whom received
four or fewer doses of sebelipase alfa
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including WFA, hepatomegaly, lymphadenopathy, and
presence of anti-drug, anti-enzyme, or anti-uptake
antibodies. The current clinical status, documented
presence of ADAs, and reasons for dose escalations
for each of the five ongoing patients are summarized
in Additional file 1: Table S1.
LIPA mutation data were available for six patients
(Additional file 1: Table S2, LAL enzyme activity and
LIPA genotypes). None of them had a copy of the previ-
ously described c.894 G > A common exon 8 splice junc-
tion mutation, which is commonly found in LAL
deficiency presenting in children and adults [23, 24].
Two patients were homozygous and one patient hetero-
zygous for documented causative mutations. The three
other patients with genotyping data were either homozy-
gous (one patient) or heterozygous (two patients) for
undocumented mutations. In the three patients without
confirmed pathological mutations, LAL deficiency diag-
nosis was confirmed based on LAL enzyme activity
testing (Additional file 1: Table S2, LAL enzyme activity
and LIPA genotypes).
In addition to growth failure, diarrhea, vomiting, ab-
dominal distension, and marked hepatosplenomegaly at
baseline, patients had anemia (n = 6), adrenal calcification
(n = 9), ascites (n = 4), and/or thrombocytopenia (n = 3)
(Table 1). The baseline liver parameters revealed signifi-
cant underlying liver injury/dysfunction with a median
ALT level of 145 U/L (2.42 μkat/L) (range 16.0–297.0 U/L
[0.27–4.96 μkat/L]) and median AST level of 125 U/L
(2.09 μkat/L) (range 71.0–716.0 U/L [1.19–11.96 μkat/L]),
and abnormally high GGT and total bilirubin levels
in four and three patients, respectively (Additional
file 1: Table S3). Although baseline high-density lipo-
protein cholesterol and triglyceride levels were abnormal
in most patients, no consistent pattern of abnormality was
seen in low-density lipoprotein cholesterol levels (data not
shown). Supportive treatments during the screening
period included a low-fat/low-cholesterol diet, nutritional
supplements including medium-chain triglyceride for-
mula, parenteral nutrition, administration of bile acid
chelators such as cholestyramine, and transfusions.
Survival
The primary endpoint of survival to 12 months of age
was met by six of the nine patients (67%; exact 95% CI
29.9–92.5) and all six patients were alive as of June 10,
2014 (ages 12.0, 15.7, 15.8, 20.4, 25.1, and 42.2 months).
Of the three patients who died before age 12 months,
two received only one infusion and one received only
four infusions of sebelipase alfa; these deaths were
deemed not related or unlikely to be related to the drug.
The median age at death for the three deceased patients
was 2.9 months (range 2.8–4.3 months). One of the six
surviving infants at 12 months died at 15 months of age.
For this patient, the stated cause of death based on
autopsy findings was sudden cardiac death, which was
assessed as unlikely to be related to sebelipase alfa. This
Table 1 Patient demographics and baseline disease
characteristics (full analysis set)
Parameter Patients (N = 9)
Age at treatment initiation, months









Age at symptom onset, months
Range 0–5.0
Age at diagnosis, months
Range 0–5.8
LAL deficiency manifestations, n (%)
Hepatosplenomegaly 9 (100)
Abdominal distension 9 (100)
Vomiting 9 (100)
Diarrhea 9 (100)
Adrenal calcifications 9 (100)
Failure to thrive 9 (100)
Anemia 6 (67)
Ascites 4 (44)
Thrombocytopenia (<150 × 109/L) 3 (33)
Hematological parameters, median (range)
Hemoglobin, g/L 93 (1.4–103.0)
Platelets, 109/L 173 (2.6–563)
Serum ferritin, μg/L, median (range) 586 (253–48,740)
Multiple organ dysfunction syndrome, n (%) 3 (33)
Growth failure/entry criteria met,† n (%)
Weight decreasing across ≥2 of the 11
major centiles
7 (78)
Body weight <10th centile and no weight
increase during 2 weeks before screening
1 (11)
Loss of >5% of birth weight after 2 weeks
of age
0
Rapidly progressive course of LAL deficiency
without meeting growth failure criteria
1 (11)
All hematological analyses were performed by local laboratories; assessment
of normal/abnormal results was based on the age- and gender-specific normal
range provided by the local laboratory at the time of the test
*Race was not reported for three patients enrolled and treated in France in
compliance with that country’s regulations
†Patients were required to meet at least one of these criteria
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infant manifested other comorbidities not typically asso-
ciated with LAL deficiency including arterial hyperten-
sion, which preceded the diagnosis of LAL deficiency, a
patent foramen ovale, and hemoglobin E disease. The
hypertension, which existed prior to enrollment in the
study, was thought to be associated with fluid overload
and was being treated with furosemide, amlodipine, and
clonidine. Elevated levels of renin and aldosterone were
observed; however, renal size (measured by ultrasound)
was within the upper limit of the normal range. Post-
mortem findings included evidence of early cirrhosis in
the liver. The lungs and intestine showed xanthomatous
changes; also spleen and bone marrow showed wide-
spread lipid vacuoles and lipid-laden macrophages, con-
sistent with underlying disease. Results of Kaplan-Meier
survival analyses are shown in Fig. 2 for the patients
receiving sebelipase alfa and for untreated patients with
growth failure in the historical control group (data on file,
Alexion Pharmaceuticals, Inc.) [7]. Survival at age
12 months in the historical control group (n = 21) was 0%
(exact 95% CI 0–16.1).
The remaining five patients have survived to ≥24 months
of age (median 3 years, 4 months [range 2 years,
11 months to 5 years, 2 months]) as of the January 26,
2016 extension analysis cut-off date, and all have contin-
ued to receive sebelipase alfa treatment; survivors’ median
time in the study at the cut-off date was 2 years,
10 months (maximum duration of exposure to study
drug was 4 years, 9 months).
Effects on growth and other important disease-related
abnormalities
All six patients who survived beyond week 4 and
reached 12 months of age exhibited increases in WFA
centile during treatment with sebelipase alfa (median
baseline WFA, 3rd [3.08] centile; n = 8) (Fig. 3). The
age ≥24-month extension period analysis showed that
two of the five surviving patients reached near or
above the 75th WFA centile, two patients reached near
or above the 25th WFA centile, and one patient
remained stabilized near or above the 5th WFA centile.
As shown in Fig. 3, initial dose escalations occurred
early during treatment. Three patients had additional
dose escalations after 12 months of age; in one patient
the dose was escalated from 1 mg/kg to 3 mg/kg and
in two patients the doses were escalated from 3 mg/kg
to 5 mg/kg. WFA centile also stabilized; at the last
available assessment among the five ongoing patients,
median WFA was in the 32nd (31.8) centile.
At baseline, median LFA was 1.8% (n = 8). Post-baseline
LFA data were available for six patients surviving beyond
week 4; LFA fluctuated but showed an overall improvement
in three patients (a decrease and return to baseline level in
two patients and a decrease in one patient). The proportion
of patients who met criteria for undernutrition in the
primary analysis set decreased with treatment (Additional
file 1: Table S4, Proportion of patients meeting criteria for
undernutrition in the primary analysis [patients who
survived to age 12 months]).
Fig. 2 Survival from birth to 12 months of age. Kaplan-Meier analyses of (a) historical control group of untreated patients with early
growth failure (n = 21) from natural history study of infants with LAL deficiency (LAL-1-NH01; data on file, Alexion Pharmaceuticals, Inc.)
[7] and (b) the primary efficacy set of the present phase 2/3 study (N = 9). Patients in the historical control group were considered
untreated if they had not received hematopoietic stem cell transplant, liver transplant, or enzyme replacement therapy. Growth failure was
defined by 1) decreased body weight across ≥2 of the 11 major centiles on a standard WHO weight-for-age chart, or 2) body weight in kilograms
below the 10th centile on a standard WHO weight-for-age chart and no weight gain for the previous 2 weeks, or 3) loss of ≥5% of birth weight
in children who are >2 weeks of age
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Rapid decreases were noted in ALT, AST, and total
bilirubin levels with sebelipase alfa treatment and these
effects were seen with the initial dose of 0.35 mg/kg
(Fig. 4; Additional file 1: Table S3). Normalization of
transaminase levels was achieved for four of the six
patients with elevated baseline AST and all four patients
with elevated baseline ALT, with normal levels achieved
between weeks 1 and 5. GGT levels decreased markedly
over the first 3 months of treatment and stabilized there-
after, with median reductions from baseline of 40.0 U/L
(0.67 μkat/L) by week 12 (n = 5). As of the cut-off date
for the analysis at ≥24 months of age, ALT had decreased
from baseline by as much as 67% and was below the upper
limit of normal in four of the five patients; AST had de-
creased by as much as 67% (Additional file 1: Table S5).
Biochemical improvements were accompanied by im-
provements in clinical symptoms of diarrhea, vomiting,
and abdominal distension, with reductions in liver and
spleen size assessed by physical examination and/or
abdominal ultrasound.
Hemoglobin levels were abnormal at baseline (n = 9;
median 93.0 g/L; range 1.4–103.0 g/L; reported as low in
six patients). Five patients achieved TFHN of at least
4 weeks during treatment before the primary analysis
data cut-off date. Two patients achieved TFHN mainten-
ance (transfusion-free at week 6 and hemoglobin levels
below the age-adjusted lower limit of normal at week 8
and continuing for ≥13 weeks). At the age ≥24 months
analysis cut-off date, hemoglobin had increased from
baseline in four of the five ongoing patients and was
unchanged from baseline in the remaining patient
(Additional file 1: Table S5). None of the five ongoing
patients required blood transfusion since age 1 year,
11 months. At the primary analysis cut-off date, require-
ments for nutritional support were reduced (eliminated
for two patients), and at the age ≥24 months analysis, no
patients were receiving parenteral nutrition; four were
receiving medium-chain triglyceride formula and a
reduced-fat diet, and one was receiving an unrestricted
diet. Albumin had increased from baseline in three of the
five ongoing patients, and slightly decreased in one patient
(Additional file 1: Table S5). Median baseline platelet
count was 173.0 × 109/L (n = 9; range 2.6–563.0 × 109/L;
reported as low in four patients). Platelet counts demon-
strated increasing trends from baseline. Serum ferritin
levels were elevated at baseline for six of the seven pa-
tients with available data; the median value was 586 μg/L
(range 253–48,740 μg/L). Rapid and marked decreases in
serum ferritin values were observed following initiation of
treatment with sebelipase alfa. By week 1, median
levels changed by −122 μg/L (range −6934 to −72 μg/
L; n = 4) and by week 6 levels changed by −269 μg/L
(range −11,171 to −215 μg/L; n = 3). At last reading,
ferritin values for the five surviving patients were all
Fig. 3 Individual growth curves over time for the 6 patients who met the primary endpoint (12-month survival). ADA = time at anti-drug antibody
detection. *Due to the window of time associated with scheduled assessments, no weight was collected at 12 months for patient 05–001;
therefore, the next available weight data point was used to graph the weight at 12 months; this patient died at age 15 months
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within normal limits (range 38 to 90 μg/L). Hypertriglyc-
eridemia was observed in four of the six patients with
measurements at baseline. At the primary analysis, all four
patients had decreases in serum triglycerides following ini-
tiation of sebelipase alfa and had achieved a normal serum
triglyceride level. High-density lipoprotein cholesterol
levels were low at baseline or the first available assessment
in all six surviving patients, and increased in five of these
patients during treatment. Low-density lipoprotein choles-
terol levels decreased in five of the six surviving patients
during treatment, and normalized in the two patients who
had an elevated low-density lipoprotein cholesterol level
at baseline or the first available assessment.
Developmental milestones
Denver II Developmental Screening Test data were
available at baseline for only three patients, due to a
requirement that patients had to be at least 1 month
of age on the date of the assessment and be suffi-
ciently responsive to be testable for each skill area of
the test. At week 24 (n = 5), fine motor–adaptive,
language, and personal-social skills were normal in
four patients and suspect in one patient. Gross
motor skills were classified as normal in two patients
and suspect in three patients. Data at later time
points were consistent with those from week 24 in
that development was found to be mostly normal,
with no patient untestable for any skill area. At the
age ≥24 months analysis, four of the five ongoing
patients tested normal on the Denver II Developmen-
tal Screening Test assessment; one patient was
assessed as normal in three of four categories but
classified as suspect in language. The oldest patient
in the study entered preschool at age 3 and has been
attending school without any reported difficulties
compared with his peers.
Fig. 4 Changes in serum transaminases. Individual patient results for transaminases over time: (a) alanine aminotransferase (ALT) and (b) aspartate
aminotransferase (AST). EBV = Epstein-Barr virus; qow = every-other-week dosing. To convert to SI units (μkat/L), multiply by 0.0167
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Safety
Adverse events in the overall population (primary effi-
cacy set) are summarized in Table 2; adverse events by
time interval of treatment are summarized in Table 3.
Reported adverse events were mainly attributable to
complications and comorbidities associated with LAL
deficiency. Treatment-emergent adverse events (defined
in Additional file 1, eDefinition of treatment-emergent
adverse events) that were reported for two or more
patients are shown in Additional file 1: Table S6; 94% of
the treatment-emergent adverse events reported
throughout the primary treatment and extension periods
were considered mild to moderate in severity. For the
primary efficacy analysis, moderate to severe IARs
occurred in three patients in association with 47 of the
462 infusions administered. As of January 26, 2016 a
majority of the 54 IARs were mild or moderate (eg,
fever, vomiting). Four treatment-related serious adverse
events, which were IARs, occurred in a single patient
(pyrexia, pallor, chills, tachycardia) in association with
the same infusion. Three of these IARs were considered
severe. The patient was hospitalized overnight and re-
ceived intravenous antibiotics for possible line bacteremia;
all culture results were negative. A total of 54 IARs
occurred in five patients over the course of their treat-
ment. All other IARs (Additional file 1: Table S7 for a
summary of IARs) were successfully managed by modifi-
cations to infusion rates and treatment with antipyretics,
antihistamines, and anti-inflammatories. None of the IARs
was consistent with anaphylaxis, and none resulted in
discontinuation of study treatment. Four patients devel-
oped ADAs during treatment with sebelipase alfa, only
one of whom remained ADA-positive through the primary
data cut-off date. Two of the four ADA-positive patients
tested positive for neutralizing antibodies. In one of these
patients the sebelipase alfa dose was escalated to 5 mg/kg
because of concerns about the rate of weight gain.
Discussion
LAL deficiency presenting in infancy is a medical emer-
gency with rapid disease progression and early death.
Delayed diagnosis or misdiagnosis is common, as the
disease is under-recognized as a cause of marked failure
to thrive and rapidly progressive liver failure in infants
and currently is not included in newborn screening.
Historical attempts at treatment including HSCT have
been almost uniformly unsuccessful [7]. Sebelipase alfa
was recently approved by the US Food and Drug
Administration and the European Commission for long-
term ERT in patients of all ages with LAL deficiency
[25]. The current report describes the first experience of
sebelipase alfa use in infants with rapidly progressive
LAL deficiency. In this study we found that enzyme
replacement with sebelipase alfa was effective, as
reflected in the outcome of survival, with six of nine
patients surviving through to the primary endpoint at
12 months of age; this is in marked contrast to outcomes
in a matched historical control group of untreated
patients, in which no patient survived to 12 months of
age (data on file, Alexion Pharmaceuticals, Inc.) [7]. The
historical control group is from a natural history study
intended to characterize LAL deficiency and disease pro-
gression, and to inform future clinical trial design. Inher-
ent variability of the dataset was consistent with the
small number of patients from diverse geographical
areas who were diagnosed over a broad period of time.
Nevertheless, these data provided valuable information
on commonalities in the presentation and disease course
of LAL deficiency that were confirmed by the findings of
the present study.
Table 2 Summary of adverse events
Event, n (%) Overall (N = 9)
Any TEAE 9 (100)
Any related TEAE 6 (67)
Any IAR 5 (56)
Any serious TEAE 9 (100)
Any related serious TEAE 1 (11)
Dose modification due to a TEAE* 7 (78)
Discontinuation due to a TEAE 0
Death 4 (44)
Death related to treatment 0
IAR infusion-associated reaction, TEAE treatment-emergent adverse event
*All dose modifications were dose escalations based on inadequate clinical
response. These symptoms of inadequate clinical response were also captured
as adverse events (see Additional file 1)
Table 3 Summary of adverse events by treatment time interval
Treatment time interval






Any TEAE 8 (89) 5 (83) 6 (100)
Any related TEAE 4 (44) 1 (17) 3 (50)
Any IAR 3 (33) 2 (33) 3 (50)
Any serious TEAE 7 (78) 4 (67) 4 (67)
Any related serious TEAE 1 (11) 0 0
Dose modification due
to a TEAE†








IAR infusion-associated reaction, TEAE treatment-emergent adverse event
*Non-serious adverse event data were unavailable for one patient from week 0
to week 39 (~month 9)
†All dose modifications were dose escalations based on inadequate clinical
response. These symptoms of inadequate clinical response were also captured
as adverse events (see Additional file 1)
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The clinical presentation and laboratory abnormalities
were consistent with those reported in the literature,
with early onset and prominent failure to thrive and
severe hepatic disease as evidenced by massive hepato-
megaly, elevation of transaminases, hyperbilirubinemia,
coagulopathy, and hypoalbuminemia [26, 27]. Adrenal
calcification, which was observed in all patients in this
study, is not always seen in infantile-onset LAL defi-
ciency [7]. The abnormalities in serum triglyceride, low-
density lipoprotein cholesterol, and high-density lipopro-
tein cholesterol levels observed for all six patients with
baseline data suggest that rapidly progressive, early-
onset LAL deficiency in infants is not associated with
the typical dyslipidemia pattern seen in children and
adults with later-onset LAL deficiency. This lipid profile
in infants may be due to fat malabsorption and the
resulting severely poor nutritional status of the patients.
Evidence of macrophage activation was seen in some
patients including cytopenias and elevated ferritin levels,
likely secondary to lipid accumulation in macrophages.
LAL deficiency is not typically considered in the differ-
ential diagnosis of hemophagocytic lymphohistiocytosis,
which has resulted in the presumptive diagnosis and treat-
ment for familial hemophagocytic lymphohistiocytosis in
some cases [28, 29].
In addition to improved survival compared to un-
treated patients, survival in sebelipase alfa–treated
patients was also prolonged relative to transplanted
patients in the historical control group (data on file,
Alexion Pharmaceuticals, Inc.) [7]. The improvements in
survival with sebelipase alfa were accompanied by clinic-
ally meaningful improvements in growth, liver function,
and hematological parameters and evidence of normal
development. Five of the six patients who survived to
12 months of age continue with ongoing sebelipase alfa
treatment. These patients have transitioned from being
hospitalized in a high-dependency setting to life at home
with outpatient infusions; elimination of requirements
for transfusions was observed in all patients who sur-
vived to 12 months of age. It is imperative that nutri-
tional needs be closely monitored, and frequent
adjustments were made to meet the nutritional needs of
each patient during treatment with sebelipase alfa. In
general, all surviving patients have experienced a reduc-
tion in the need for nutritional support and none are
currently receiving parenteral support. Initiation of treat-
ment with sebelipase alfa at doses equal to or greater
than 0.35 mg/kg produced rapid stabilization and/or
improvements in growth and other disease-related ab-
normalities including markers of liver injury; this was
consistent with preclinical results in an animal model of
LAL deficiency (Quinn AG, et al. Abstract presented at
the 2010 Annual Meeting of the American Society of
Human Genetics, Washington, DC). The rapid decreases
in serum transaminases observed for patients in this
study are consistent with findings from a previous phase
1/2 study of sebelipase alfa in adults with LAL deficiency
(LAL-CL01/CL04) [18, 30]. Five of the six patients who
survived to age 12 months had their weekly dose esca-
lated to 3.0 mg/kg after a variable period receiving
1 mg/kg, and one patient (01–002) underwent a further
dose escalation to 5.0 mg/kg, primarily because of con-
cerns related to the rate of weight gain. Another patient
(01–003) was also dose escalated to 5 mg/kg weekly.
This patient had been progressing well on a dose of
3 mg/kg administered once weekly and was permitted to
go onto an every-other-week infusion schedule. How-
ever, this was not successful and resulted in hypoalbu-
minemia and disturbed transaminases. The patient was
restored to a 3 mg/kg once-weekly dose schedule but
showed no improvement and doses were subsequently
escalated to 5 mg/kg given once weekly. At the time of
the data cut-off, all five of the dose-escalated patients
had improvement in WFA across two or more major
centiles compared with their baseline values.
The protocol was amended during the course of the
study to allow for higher doses of sebelipase alfa than
were originally planned. No human studies had been
conducted and there was no human experience with
sebelipase alfa in LAL deficiency prior to the initiation
of the current study in 2011. Given the lack of available
data, safety was the most important consideration at the
time the study was initiated. Thus, a starting dose of
0.35 mg/kg given once weekly was deemed to be the
minimally effective dose, and it was anticipated that
doses of up to 3 mg/kg would be required based on data
obtained from preclinical studies of sebelipase alfa in
animal models of LAL deficiency. Some patients devel-
oped antibodies to sebelipase alfa during the study,
which could potentially neutralize the efficacy of the
study drug. As a result of these observations, further
dose escalations to 5 mg/kg per week were allowed at
the discretion of the study investigators. Although im-
provements in a number of parameters were seen with
the initial 0.35 mg/kg dose, given the rapid disease pro-
gression in infants and potential for development of
ADAs, further investigation of higher sebelipase alfa
doses may be warranted. Other limitations of this study
are the small sample size, and the requirement to use a
historical control group for the assessment of efficacy
given the rapid and fatal course of the untreated disease.
Sebelipase alfa was generally well tolerated. Although
IARs were seen in all patients, they were successfully
managed with approaches commonly used with other
ERTs. Two of the five currently ongoing patients have
experienced frequent IARs; these events have been well
managed by site personnel and have not impacted their
treatment. The safety experience with sebelipase alfa to
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date appears favorable given the medical condition of
infants with rapidly progressive disease.
Conclusions
We describe the first experience with sebelipase alfa in
infants presenting with LAL deficiency. The observed
beneficial effects include survival well beyond the usual
life expectancy in affected infants with improvements in
growth, liver injury and function, reductions in hepatos-
plenomegaly, amelioration of cytopenias, and attainment
of developmental milestones. Given the historical mor-
bidity and mortality in infants with LAL deficiency,
including rare patients treated by HSCT, early treatment
with sebelipase alfa represents an important advance in
the management of these patients. The rapidity of
disease progression and its impact on the effects of
enzyme replacement highlight the importance of early
diagnosis of this life-threatening disease.
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